GLOBAL MARKET RESEARCH REPORT

Porcine Epidemic Diarrhea (PED)

Vaccines Market

Global Industry Analysis, Segment Intelligence, Competitive Landscape & Strategic Outlook

Forecast Period: 2026 – 2036

Base Year: 2025  |  Published: 2025Confidential – For Business Use Only

The global Porcine Epidemic Diarrhea (PED) Vaccines market represents one of the most strategically significant segments within the veterinary biologics industry. As swine producers worldwide contend with recurring outbreaks of PED virus (PEDV), vaccine adoption has become a cornerstone of biosecurity planning for commercial pig operations.

The market was valued at approximately USD 320 million in 2025 and is projected to surpass USD 610 million by 2036, reflecting a compound annual growth rate (CAGR) of approximately 6.2% over the forecast period. Growth is underpinned by the expanding global pig population, heightened disease surveillance programs, government-supported livestock health initiatives, and rapid vaccine technology innovation across major pork-producing economies.

1.1 Introduction to Porcine Epidemic Diarrhea

Porcine Epidemic Diarrhea (PED) is a highly contagious intestinal disease caused by the Porcine Epidemic Diarrhea Virus (PEDV), an Alphacoronavirus. First identified in Europe in the 1970s and later causing catastrophic outbreaks in Asia and North America through the 2010s, PEDV results in severe acute diarrhea, vomiting, and near 100% mortality in neonatal piglets less than one week old. The economic ramifications of a single outbreak on a large commercial swine farm can reach hundreds of thousands of US dollars in mortality losses, treatment costs, and delayed production cycles.

Vaccination remains the most viable long-term strategy for outbreak prevention and herd immunity management. The PED vaccines market encompasses live attenuated vaccines, inactivated (killed) vaccines, subunit vaccines, virus-like particle (VLP) vaccines, and emerging nucleic acid platforms.

1.2 Market Scope & Definition

This report examines the commercial market for vaccines specifically targeting PEDV across all geographies, product types, distribution channels, and end-user categories. The analysis covers both preventive and emergency response vaccine programs, including government-mandated vaccination schemes in high-risk countries.

2.1 By Vaccine Type

The PED vaccines market is segmented by vaccine formulation technology into five distinct categories, each with unique immunological profiles, cold-chain requirements, and regulatory pathways.

Inactivated vaccines command the largest market share due to their established safety record, suitability for administration to pregnant sows, and regulatory acceptance across major markets. However, mRNA-based platforms are attracting significant R&D investment following the validation of nucleic acid technologies in human medicine, and are expected to capture a meaningfully larger share by 2036.

2.2 By Application / End-Use

Vaccine application can be categorized by pig lifecycle stage and the intended immunological outcome — whether to directly protect the animal or to confer passive immunity to offspring.

2.3 By Distribution Channel

•     Veterinary Clinics & Practitioners — Direct prescription-based supply; preferred for high-value herds

•     Veterinary Pharmaceutical Distributors — Dominant channel by volume; covers bulk supply to large integrators

•     Online Veterinary Pharmacies — Growing channel, especially post-pandemic; cold-chain logistics remain a constraint

•     Government Procurement & Public Veterinary Services — Significant in Asia-Pacific and Latin America for subsidized programs

•     Direct Manufacturer-to-Farm Supply Agreements — Emerging model for large integrated pork producers

Regional performance in the PED vaccines market is closely correlated with swine inventory size, disease endemicity, regulatory infrastructure, and the maturity of the veterinary biologics sector. The following analysis covers six major geographies.

Asia-Pacific is anticipated to retain its dominant position throughout the forecast period, driven by the sheer scale of pig populations in China (hosting roughly half the world's pig inventory), Vietnam, and South Korea — all of which face recurring PEDV challenges. Government-subsidized vaccination in these countries further amplifies market volume.

The global PED vaccines market is moderately consolidated, with established veterinary pharmaceutical multinationals competing alongside specialized regional biologics firms. Innovation, manufacturing scale, regulatory breadth, and distribution reach are the primary competitive differentiators.

The following analysis evaluates competitive intensity and market attractiveness in the global PED vaccines sector through the lens of Michael Porter's Five Forces framework.

The SWOT framework below evaluates the global PED vaccines market from a strategic standpoint, encompassing both internal market characteristics and external environmental factors.

7.1 Technological Trends

The most consequential technological trend shaping the market is the translation of mRNA vaccine platforms from human health applications into veterinary use. Several players are investing in thermostable lipid nanoparticle formulations that could alleviate cold-chain dependency — a critical factor for market expansion in tropical and infrastructure-limited regions.

Recombinant subunit vaccines expressing the spike (S) protein of PEDV are advancing through regulatory review in multiple jurisdictions, offering highly targeted immune responses with minimal adverse effects. Additionally, VLP-based vaccines that mimic the virus structure without containing genetic material are gaining traction as premium alternatives for high-value breeding stock.

7.2 Commercial & Market Trends

•     Combination Vaccine Development: Manufacturers are developing multivalent products targeting PEDV alongside Porcine Deltacoronavirus (PDCoV), Transmissible Gastroenteritis Virus (TGEV), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) to reduce the overall vaccination burden on farms.

•     Contract Manufacturing Organizations (CMOs): Smaller innovators are increasingly outsourcing GMP biologics production to specialist CMOs, reducing capital expenditure and accelerating time-to-market.

•     Outcome-Based Procurement Models: Large pork integrators are pushing for pay-for-performance vaccine contracts tied to measurable herd health outcomes, shifting commercial risk toward vaccine manufacturers.

•     Personalized / Farm-Specific Vaccines: Autogenous vaccine programs — custom-formulated from field-isolated strains — are growing in adoption, particularly in North America and Europe, offering tailored protection against locally circulating PEDV variants.

7.3 Regulatory Trends

Regulatory agencies in the United States (USDA APHIS), European Union (EMA), and China (MARA/NMPB) are progressively updating biologics frameworks to accommodate novel vaccine platforms including nucleic acid-based products. Accelerated review pathways for emergency-use veterinary vaccines — modeled on mechanisms used during zoonotic disease outbreaks — are being codified in several jurisdictions, which will materially shorten development cycles.

8.1 Key Market Drivers

8.2 Key Market Challenges

The PED vaccines value chain is characterized by high scientific complexity in upstream stages and logistical sensitivity throughout midstream and downstream distribution.

The COVID-19 pandemic introduced significant disruption across the animal health supply chain between 2020 and 2022. Initial impacts included manufacturing delays due to workforce restrictions, logistical bottlenecks in cold-chain distribution, and diversion of regulatory resources toward human health priorities. These factors temporarily suppressed PED vaccine procurement volumes, particularly in Southeast Asia and Latin America.

However, the pandemic produced several enduring structural benefits for the veterinary biologics sector. Accelerated mRNA platform validation in human medicine materially shortened the technology transfer timeline to animal health applications. Heightened awareness of zoonotic disease risks prompted governments in multiple regions to increase livestock biosecurity budgets — a tailwind that directly benefits the PED vaccines market.

By 2023, the market had returned to and exceeded pre-pandemic revenue trajectories, with several manufacturers reporting record order volumes driven by pent-up demand and new government vaccination mandates. Supply chain resilience investments made during the pandemic are expected to generate long-term operational efficiency benefits through the forecast period.

For Vaccine Manufacturers

•     Prioritize investment in thermostable formulations and lyophilized vaccine presentations to eliminate cold-chain constraints and unlock rural and developing-market penetration opportunities.

•     Accelerate development of polyvalent (combination) vaccines covering PEDV alongside other economically significant enteric pathogens such as PDCoV and TGEV, reducing per-dose administration cost for producers.

•     Establish regional strain surveillance partnerships with national veterinary authorities to proactively update vaccine antigens ahead of field-strain divergence.

•     Explore strategic M&A and licensing in Latin America and Southeast Asia to build distribution infrastructure ahead of anticipated market growth in these regions.

For Pork Producers & Integrators

•     Implement comprehensive whole-herd vaccination protocols anchored on sow vaccination programs, ensuring passive immunity transfer to neonatal piglets as the primary PEDV mortality prevention strategy.

•     Engage with veterinary service providers to conduct regular field-strain typing to validate cross-protection of currently deployed vaccines against locally circulating PEDV variants.

•     Leverage farm management platforms with integrated vaccination scheduling and efficacy tracking modules to optimize herd health ROI.

For Investors & Financial Stakeholders

•     Target companies with active mRNA veterinary biologics pipelines and existing regulatory relationships in Asia-Pacific — this combination represents the highest near-term revenue upside.

•     Evaluate cold-chain logistics firms serving veterinary biologics as a complementary investment theme, as infrastructure expansion in emerging markets is a prerequisite for PED vaccine market growth.

•     Monitor regulatory milestones around DIVA-compatible and combination vaccine approvals as key value inflection events for pipeline-stage companies.

For Regulators & Policy Bodies

•     Develop harmonized international standards for PEDV vaccine efficacy testing to reduce duplicative trial burdens and accelerate global product availability.

•     Expand government cost-sharing or subsidy mechanisms for smallholder swine farmers in PEDV-endemic lower-income countries to ensure equitable access to effective vaccination programs.

•     Establish adaptive regulatory pathways for next-generation veterinary vaccine platforms (mRNA, VLP) that allow conditional approval based on early field data with structured post-market surveillance requirements.

This report has been prepared for informational and strategic planning purposes. All market size estimates, CAGRs, and projections are derived from independent analysis of publicly available industry data, company disclosures, and expert consultations. The figures presented are approximations and subject to revision based on evolving market conditions. This document does not constitute investment advice.